Growing diagnostics Inanovate focuses on a proteomics platform for tick-borne disease and cancer/autoimmune diagnostics, presenting a potential cross-sell opportunity for expanded diagnostic panels and treatment monitoring solutions to existing customers in medical devices and lab testing.

Expansion potential Headquartered in Sioux Falls with engineering and production in Chapel Hill, the company has a distributed footprint that could enable regional partnerships, contract manufacturing arrangements, and regional pilot programs to accelerate go-to-market in multiple U.S. regions.

Funding signals With a Series C financing of 3.1 million and total funding around 13 million, there is visible investor appetite and runway to scale platforms, suggesting readiness to engage strategic buyers and co-development partners.

Revenue mix Current revenue range of one to ten million indicates early-stage commercial traction; leverage this to position higher-value, integrated diagnostics packages, service agreements, and data analytics offerings to existing and new customers.

Industry fit Target customers include biotech and diagnostics firms focused on cancer, autoimmune diseases, and infectious diseases; pursue partnerships with large life science suppliers or contract research organizations seeking advanced proteomics capabilities and rapid diagnostic deployment.